MADRID (Reuters) - Two AstraZeneca drugs tackling lung cancer in different ways delivered encouraging results on Saturday, helping the British group offset July's big clinical trial setback in the disease.
LONDON (Reuters) - A clinical study testing AstraZeneca's experimental immunotherapy drugs in lung cancer patients who have already received at least two previous treatments will take longer than initially expected to produce result...
ZURICH (Reuters) - A drug Roche had hoped would prevent loss of vision and become a big seller failed a late-stage trial, leading some analysts to say on Friday it now had no future.
LONDON (Reuters) - AstraZeneca's ovarian cancer drug Lynparza slowed disease progression sharply in a closely watched clinical trial, boosting hopes for a product that belongs to a novel drug class called PARP inhibitors.
LONDON (Reuters) - AstraZeneca's combination of two immunotherapy drugs, durvalumab and tremelimumab, failed to help patients as hoped in a closely watched advanced lung cancer trial, the British company said on Thursday.